What the FDA labels say about taking them together
Riociguat and tadalafil
Riociguat's FDA label of August 13, 2026 names tadalafil in its contraindications section, and tadalafil's label names riociguat too. The tadalafil label: “Cyclase (GC) Stimulators Coadministration of GC stimulators such as riociguat with TADLIQ is contraindicated.”
Check it at the source: the riociguat FDA label on DailyMed (effective August 13, 2026, Bayer HealthCare Pharmaceuticals Inc.); the tadalafil FDA label on DailyMed (effective June 3, 2026, Eli Lilly and Company).
What does the riociguat label say about tadalafil?
Riociguat label, contraindicationsConcomitant administration of Adempas with specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) or nonspecific PDE-5 inhibitors (such as dipyridamole or theophylline) is contraindicated [see Dosage and Administration (2.6), Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.2 )].
Riociguat label, drug interactionsPDE Inhibitors: Co-administration of Adempas with specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) and nonspecific PDE inhibitors (such as dipyridamole or theophylline), is contraindicated because of hypotension.
Source: FDA drug label (Adempas), Bayer HealthCare Pharmaceuticals Inc., effective August 13, 2026 (SPL set 7b57509a-3d5d-41d4-8fed-1471e26372a3), via openFDA; the full label on DailyMed
What does the tadalafil label say about riociguat?
Tadalafil label, contraindicationsAdministration with guanylate cyclase (GC) stimulators, such as riociguat ( 4.3 ).
Adcirca label (United Therapeutics Corporation, December 15, 2025), contraindicationsCyclase (GC) Stimulators Coadministration of GC stimulators such as riociguat with ADCIRCA is contraindicated.
Source: FDA drug label (Adcirca, NDA022332), United Therapeutics Corporation, effective December 15, 2025 (SPL set ff61b237-be8e-461b-8114-78c52a8ad0ae), via openFDA
Source: FDA drug label (Tadliq, NDA214522), CMP Pharma, Inc., effective October 15, 2022 (SPL set 7a909b25-3772-403e-a5fe-e4a040293fb7), via openFDA
Source: FDA drug label (Cialis), Eli Lilly and Company, effective June 3, 2026 (SPL set bcd8f8ab-81a2-4891-83db-24a0b0e25895), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Riociguat | Tadalafil | |
|---|---|---|
| Labeled for | Pulmonary arterial hypertension | Erectile dysfunction, Enlarged prostate (BPH), Pulmonary arterial hypertension |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | $0.167 per tablet 20 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once